No Rest For Sonata: King To Develop XR Version After Acquisition From Elan
Executive Summary
King plans to develop an extended-release version of Sonata following an $850 mil. acquisition of Elan's primary care business
You may also be interested in...
Pfizer/Neurocrine File First Indiplon NDA With Eye On Q4 2005 Launch
The first of two NDA filings for Pfizer/Neurocrine's insomnia agent indiplon puts the drug on track for a launch in the fourth quarter of 2005
Pfizer/Neurocrine File First Indiplon NDA With Eye On Q4 2005 Launch
The first of two NDA filings for Pfizer/Neurocrine's insomnia agent indiplon puts the drug on track for a launch in the fourth quarter of 2005
King/Elan Deal Proceeds; Skelaxin Royalties Will Offset Lower Purchase Price
King will pay Elan royalties on sales of the muscle relaxant Skelaxin under a restructured agreement for Elan's primary care business